You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 6,884,616

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,884,616

Title:	DNA-construct for the tissue-specific expression of a blood coagulation factor
Abstract:	A DNA-construct has been disclosed which is suitable for a tissue-specific expression of a blood coagulation factor like Factor IX, which comprises a DNA coding for an amino acid sequence of a blood coagulation factor and a DNA coding for a promoter which is specific for the expression in hematopoietic cells.
Inventor(s):	Negrier; Claude (Irigny, FR), Rodriguez; Marie Helene (Lyon, FR), Enjolras; Nathalie (Caluire, FR)
Assignee:	ZLB Behring GmbH (Marburg, DE)
Application Number:	09/559,344
Patent Claims:	1. A DNA-construct for the tissue-specific expression of a blood coagulation factor comprising a DNA sequence coding for an amino acid sequence of a blood coagulation factor and a DNA sequence functioning as a promoter which is specific for expression in megakaryocytes, wherein the DNA sequence functioning as a promoter is the DNA sequence for the human platelet glycoprotein IIb (GPIIb) promoter. 2. The DNA-construct as claimed in claim 1, wherein the blood coagulation factor is Factor IX. 3. The DNA-construct as claimed in claim 1, wherein a first truncated intron (Intron 1) of the human FIX gene is inserted into the DNA sequence coding for an amino acid sequence of a blood coagulation factor. 4. A process for the production of a blood coagulation factor in a megakaryocyte cell line comprising: transfecting megakaryocyte cells with a DNA-construct coding for a blood coagulation factor comprising: a DNA sequence coding for the amino acid sequence of a blood coagulation factor, and a DNA sequence functioning as a promoter which is specific for expression in megakaryocytes; and expressing the DNA-construct. 5. The process as claimed in claim 4, wherein the production of the blood coagulation factor is stimulated by an inducer. 6. The process as claimed in claim 5, wherein the inducer is phorbol-12-myristate-13-acetate (PMA). 7. The process according to claim 4 wherein the DNA sequence functioning as a promoter is the DNA sequence for the human platelet glycoprotein IIb (GPIIb) promoter. 8. The process according to claim 4, wherein the blood coagulation factor is Factor IX. 9. The process according to claim 4, wherein a first truncated intron (Intron 1) of the human FIX gene is inserted into the DNA sequence coding for an amino acid sequence of a blood coagulation factor.

Details for Patent 6,884,616

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986	⤷ Try a Trial	2019-04-27
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132		⤷ Try a Trial	2019-04-27
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132		⤷ Try a Trial	2019-04-27
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.